Pharmaceuticals News and Research

RSS

Semafore Pharmaceuticals awarded U.S. patent covering PI-3 kinase inhibitor prodrugs

Semafore Pharmaceuticals today announced today announced the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,662,977 entitled “PI-3 Kinase Inhibitor Prodrugs.” This composition of matter patent covers a genus of novel compounds that includes SF1126, Semafore’s clinical stage, small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two key members of the PI3K signaling pathway that is vital to several essential biological processes, such as cell proliferation and survival.

25 Feb 2010

Texas-based consortium announces biotherapeutic manufacturing initiative for vaccine production

Leaders of the Texas Plant-Expressed Vaccine Consortium today announced a biotherapeutic manufacturing initiative designed to show proof of concept for a landmark new technology that could dramatically increase the nation's capability to produce vaccines for infectious diseases, including influenza.

25 Feb 2010

LGL awards first three grants from POC fund for research in immunotherapy, schizophrenia and heart disease

London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, has awarded the first three grants from its proof-of-concept (POC) fund. The awards, to teams at Imperial College London and University College London, are for research in the areas of immunotherapy, schizophrenia and heart disease.

25 Feb 2010

New book details how Greenway Medical Technologies' PrimeResearch integrates with PrimeSuite

Paper Kills 2.0: How Health IT Can Help Save Your Life and Your Money, is due out today by the Washington, D.C.-based Center for Health Transformation.

25 Feb 2010

Signaling molecules may link certain actions of B cells to solid tumor growth: Study

Cancer researchers studying the immune system have identified a previously unrecognized set of targets and biomarkers to battle solid tumors.

25 Feb 2010

Novartis Pharma agrees to further extend maturity date of Emisphere Technologies' Convertible Promissory Note

Emisphere Technologies, Inc., a biopharmaceutical company that focuses on a unique and improved delivery of pharmaceutical compounds and nutritional supplements using its Eligen® Technology, today announced that Novartis Pharma AG has agreed to further extend the maturity date of Emisphere’s Convertible Promissory Note to May 26, 2010.

25 Feb 2010

SeqWright deploys Isilon scale-out NAS storage solution for next-generation genomic sequencing services

Isilon® Systems today announced that SeqWright has deployed Isilon scale-out NAS as an end-to-end storage solution for its full range of next-generation genomic sequencing services. By combining Isilon's X-Series, NL-Series and Backup Accelerator, SeqWright has created a comprehensive solution for every stage of its DNA sequencing workflow – from primary storage, to nearline archival, to tape backup – accelerating time-to-results without requiring full-time storage administration.

25 Feb 2010

Low doses of lasofoxifene reduce all common problems in postmenopausal women: Study

Low doses of the medication lasofoxifene can reduce the risk of vertebral and non-vertebral fractures, ER-positive breast cancer, coronary heart disease and stroke in postmenopausal women with osteoporosis. That's the finding of a new study in the latest issue of the New England Journal of Medicine.

25 Feb 2010

Orexo partner submits NDA for cancer pain drug Abstral in Japan

Orexo AB today announces that its partner Kyowa Hakko Kirin Co., Ltd. has submitted the New Drug Application (NDA) in Japan for the cancer pain drug KW-2246 (Abstral).

25 Feb 2010

EpiCept provides business update and fourth-quarter financial highlights

EpiCept Corporation today announced operating and financial results for the fourth quarter and year ended December 31, 2009, and provided an update on Ceplene® and several of the Company’s key product candidates.

25 Feb 2010

Zcube joins Mission Bay Capital Fund with $1M investment

Mission Bay Capital, LLC, has added a new limited partner to its first venture fund, bolstering the fund's ability to invest in promising bioscience companies emerging from the University of California.

25 Feb 2010

Special Issue of Business Horizons addresses issues central to healthcare and life sciences

A recent Special Issue of Business Horizons (www.elsevier.com/locate/bushor), the journal of the Kelley School of Business, Indiana University, and published by Elsevier, addresses issues central to healthcare and life sciences. Healthcare reform, for example, has been at the center of U.S. political debate in recent years with renewed attempts to gain bipartisan support from Congress for passage of a national system of health insurance coverage.

25 Feb 2010

Anadys Pharmaceuticals' ANA598 combination demonstrates 73% cEVR in ongoing Phase II study for HCV

Anadys Pharmaceuticals, Inc. today announced preliminary results from an ongoing Phase II study demonstrating that 73% of hepatitis C patients treated with 200 mg ANA598 twice daily in combination with pegylated interferon and ribavirin (SOC) achieved undetectable levels of virus (<15 IU/mL) at week 12, known as complete Early Virological Response or cEVR.

25 Feb 2010

Enzon Pharmaceuticals initiates treatment in PEG-SN38 Phase 1 study for pediatric cancer patients

Enzon Pharmaceuticals, Inc. today announced that the first patient has been treated in the Phase 1 study of PEG-SN38 for pediatric cancer patients. PEG-SN38 or EZN-2208 is Enzon’s PEGylated form of SN38, the active metabolite of the cancer drug Camptosar® (irinotecan HCl injection). The study is designed to find the recommended dose of PEG-SN38 in pediatric patients. The PEG-SN38 compound is currently being evaluated in Phase 2 studies for metastatic colorectal and breast cancer.

24 Feb 2010

Unique technology identifies drug candidates, speeds up drug development

The search for new therapeutic agents is time-consuming and expensive. Pharmaceutical companies may have to screen thousands of compounds for the ability to bind a target molecule before they hit upon a promising drug candidate.

From NanoTemper Technologies 24 Feb 2010

Novelos Therapeutics' NOV-002 Phase 3 NSCLC trial fails to meet primary survival endpoint

Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the primary endpoint of improvement in overall survival was not met in Novelos’ pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) studying its lead product, NOV-002, in combination with first-line chemotherapy. Detailed trial results are expected to be presented via appropriate scientific venue later this year.

24 Feb 2010

FDA approves Wyeth Pharmaceuticals' Prevnar 13 pneumococcal disease vaccine

The U.S. Food and Drug Administration today approved Prevnar 13, a pneumococcal 13-valent conjugate vaccine for infants and young children ages 6 weeks through 5 years. Prevnar 13 will be the successor to Prevnar, the pneumococcal 7-valent conjugate vaccine licensed by the FDA in 2000 to prevent invasive pneumococcal disease (IPD) and otitis media. The new vaccine extends the protection to six additional types of the disease causing bacteria.

24 Feb 2010

FDA accepts Arena Pharmaceuticals' lorcaserin NDA

Arena Pharmaceuticals, Inc. announced today that its New Drug Application (NDA) for lorcaserin, Arena's internally discovered and developed drug candidate for weight management, including weight loss and maintenance of weight loss, has been accepted for filing by the US Food and Drug Administration (FDA). Arena submitted the lorcaserin NDA on December 22, 2009, and expects to learn the Prescription Drug User Fee Act (PDUFA) date in the next few weeks. The PDUFA date is the target date for the FDA to complete its review of an NDA.

24 Feb 2010

Shire receives FDA Fast Track designation for REPLAGAL

Shire plc, the global specialty biopharmaceutical company, announces it has received Fast Track designation from the FDA for REPLAGAL(R) (agalsidase alfa), its enzyme replacement therapy for Fabry disease.

24 Feb 2010

ViroPharma reports 76% growth in fourth-quarter net product sales

ViroPharma Incorporated reported today its financial results for the fourth quarter and year ended December 31, 2009.

24 Feb 2010

Pharmaceuticals News and Research

Semafore Pharmaceuticals awarded U.S. patent covering PI-3 kinase inhibitor prodrugs

Texas-based consortium announces biotherapeutic manufacturing initiative for vaccine production

LGL awards first three grants from POC fund for research in immunotherapy, schizophrenia and heart disease

New book details how Greenway Medical Technologies' PrimeResearch integrates with PrimeSuite

Signaling molecules may link certain actions of B cells to solid tumor growth: Study

Novartis Pharma agrees to further extend maturity date of Emisphere Technologies' Convertible Promissory Note

SeqWright deploys Isilon scale-out NAS storage solution for next-generation genomic sequencing services

Low doses of lasofoxifene reduce all common problems in postmenopausal women: Study

Orexo partner submits NDA for cancer pain drug Abstral in Japan

EpiCept provides business update and fourth-quarter financial highlights

Zcube joins Mission Bay Capital Fund with $1M investment

Special Issue of Business Horizons addresses issues central to healthcare and life sciences

Anadys Pharmaceuticals' ANA598 combination demonstrates 73% cEVR in ongoing Phase II study for HCV

Enzon Pharmaceuticals initiates treatment in PEG-SN38 Phase 1 study for pediatric cancer patients

Unique technology identifies drug candidates, speeds up drug development

Novelos Therapeutics' NOV-002 Phase 3 NSCLC trial fails to meet primary survival endpoint

FDA approves Wyeth Pharmaceuticals' Prevnar 13 pneumococcal disease vaccine

FDA accepts Arena Pharmaceuticals' lorcaserin NDA

Shire receives FDA Fast Track designation for REPLAGAL

ViroPharma reports 76% growth in fourth-quarter net product sales

Event guide: World ADC Asia eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence